Hepatitis C and Tuberculosis Long-Acting Medicines: Analysis of Patenting Trends and Implications for Access
This new report offers recommendations to ensure access to long-acting technologies throughout the research and development process.
An Activist’s Guide to Shorter Treatment for Drug-Sensitive Tuberculosis
After a decades-long wait, shorter treatment for drug-sensitive tuberculosis (TB) for adults and children is finally possible. Two landmark clinical trials (S31/A5349 and SHINE) have demonstrated that adults, adolescents, and some children can be cured of TB in as little as four months.
Statement from TAG’s TB Project on Today’s WHO Global TB Report
Today's Global TB Report from WHO confirms our worst expectations for how COVID-19 has set back the global TB response. The pandemic has reversed an entire generation of progress. The first year-on-year increase in TB deaths since 2005 is devastating.
TAGline October 2021
Delivering on the Promise of Long-Acting Forumulations delves deep into the development of long-acting formulations for the treatment and prevention of infectious diseases like HIV, tuberculosis, hepatitis C, and malaria. Long-acting medications have become common for conditions such as osteoporosis and schizophrenia, and they're even used for birth control.
Realizing Returns on U.S. Government Investments in GeneXpert Diagnostic Technologies
GeneXpert diagnostic tests are essential tools in the struggle against COVID-19, tuberculosis, HIV, viral hepatitis, and other diseases. This brief outlines actionable steps the U.S. government can take to hold Cepheid accountable for transparent, fair, and equitable pricing of GeneXpert tests.
Substantial Public Investments in GeneXpert Underscore Need for Affordable Pricing
TAG’s comprehensive analysis found that the public invested at least $252 million USD in the research and development of GeneXpert diagnostic technology, which stands in stark contrast to the lack of affordable pricing and favorable service and maintenance terms from the diagnostics company Cepheid.
2021 Pipeline Report
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
TAG Testimonies on Funding Priorities FY22 to Senate LHHS and Related Agencies
On June 24, TAG submitted testimony to the Senate Subcommittee on Labor, Health and Human Services, Education, and Related Agencies outlining funding priorities for fiscal year 2022.
TAG Celebrates TB Advocacy Award for Senior Policy Officer Elizabeth Lovinger
TAG joins the U.S. National TB Controllers Association (NTCA) in celebrating our dedicated and brilliant Senior Government Relations and Policy Officer, Elizabeth (Lizzy) Lovinger, who today received the 2021 Charles DeGraw TB Advocacy Award.
Research in Action Awards 2021
On November 16, we honored CDC Director Rochelle Walensky, MD, MPH; Ivy Kwan Arce, activist, mother, and artist living with HIV; and Erica Lessem, MPH, former TAG Deputy Executive Director.